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Parkinson's disease (PD) is the second most common neurodegenerative disease characterized by loss of 
dopaminergic neurons in the substantia nigra. In the present study was designed to evaluate anti-Parkinson’s activity of 
ethanolic extract of Tridax procumbens (EETP) leaves, family Asteraceae. The experimental paradigm included 
haloperidol-induced catalepsy in rat model and rotenone-induced locomotor impairment in the fruit fly. In the catalepsy 
model, the rats received treatment of EETP (100 and 200 mg/kg, p.o.) followed by haloperidol (1 mg/kg, i.p.) for  
15 days. The significant (P <0.05) reduction in muscle rigidity, catalepsy at EETP (100 mg/kg) while; improved 
locomotor activity was found with the EETP (100 and 200 mg/kg, p.o.). The catalase and reduced glutathione levels were 
found to be significantly (P <0.05) increased and decreased lipid peroxidation at EETP (100 and 200 mg/kg). In fruit fly 
model; rotenone (ROT) 500 μM co-exposed with EETP (0.05% w/v and 0.1% w/v) to flies for 7 days. Treatment with 
EETP (0.05 and 0.1% w/v) significantly (P <0.05) improved the performances of locomotor activity in flies when 
compared with ROT treated flies. Thus, the study proved that EETP treatment significantly attenuated motor defects and 
also protected the brain from oxidative stress. 
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Introduction 
Parkinson’s disease (PD) is classically defined  
as a movement disorder, second-most progressive 
neurodegenerative disease after Alzheimer disease. 
PD is caused by denervation of dopaminergic neurons 
in the substantia nigra pars compacta leading to 
depletion of dopamine at the striatal level.  
The cumulative effect of increased oxidative  
DNA damage, lipid peroxidation, mitochondrial 
dysfunction, excitotoxicity, glutathione depletion, iron 
deposition and alteration in antioxidant enzymes 
activities being the main cause of PD1,2. The main 
clinical characteristics of PD include motor symptoms 
like tremors in the jaw, head, arms or legs; rigidity or 
stiffness of the limbs and trunk; bradykinesia; 
abnormalities in postural stability; impaired balance 
and festinating gait. These symptoms are led by 
psychological symptoms such as depression and more 
general non-motor symptoms such as olfactory 
dysfunction, constipation and sleep disturbances2. 
Natural products remain an important source of 
new drugs, new drug leads and new chemical entities 
for various diseases. Herbal medicines are parts of 
plants that are used to treat a range of disorders and to 
enhance wellbeing. One such plant i.e Mucuna 
pruriens (Fabaceae) has proved to be efficacious in 
Parkinson’s diseases management3. Herbal medicine 
has its origins in ancient traditional cultures including 
those of the Indians, Egyptians, American and 
Chinese. Tridax procumbens is a species of flowering 
plant in the daisy family (Asteraceae), a common 
weed and pest plant natively belongs to the tropical 
region of America4,5. It has been introduced to 
tropical, subtropical, and mild temperate regions all 
around the world. It is wildly present throughout  
India growing primarily during rainy season. Also 
known as coat button or tridax daisy (English),  
ghamra (Hindi), dagadipala (Marathi), jayantiveda 
(Sanskrit)4,5. It has been found to possess significant 
medicinal properties, extensively used in Ayurvedic 
system of medicine for a liver disorder. The plant  
has various pharmacological activities like anti-
hyperglycemic6, hepatoprotective7, anti-cancer8, 
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anti-bacterial and anti-microbial12, anti-mycobacterial13, 
anti-inflammatory14, hemostatic activity5, and anti-
trypanosomal5. Traditionally in India leaves of  
T. procumbens being used as anti-coagulant5, hair 
tonic15, anti-fungall3, insect repellent16, and wound 
healing17. 
The plants being the natural source have diverse 
phytoconstituents. The leaves of Tridax procumbens 
have a higher content of lignin viz. galgravin and 
flavonoids viz. luteolin, kaempferol, ellagic acid, 
catechin and silymarin. These lignin and flavonoids 
are reported to have antioxidant, anti-inflammatory 
and neuroprotective activity18. Thus depending on the 
actives present in Tridax procumbens it was selected 
for evaluation of anti-Parkinson’s activity. 
 
Materials and Methods 
 
Drugs and chemicals 
Haloperidol (Inj. serenace; RPG Life Sciences), 
levodopa+carbidopa (Tab. syndopa plus; Sun 
Pharma.), hydrogen peroxide (Research lab), 
thiobarbituric acid (Research lab), trichloroacetic acid 
(Research lab), 5,5-dithiobis-(2nitrobenzoic acid) 
(HiMedia), ethanol (S.D Fine Chem.), rotenone 
(Sigma Aldrich). 
 
Collection of plant material 
The powder of Tridax procumbens leaves was 
obtained from Ambaji Ayurved Bhavan, Mulund; 
Mumbai. The powdered drug was identified and 
authenticated (BSI/WRC/100-1/Tech/2017/H1-34) by 
Dr Priyanka Ingle, Botanical Survey of India, Pune. 
 
Preparation of plant extract 
The powder was packed in a soxhlet extractor and 
extracted with 95% ethanol at 50 °C. Extraction was 
carried out for 72 hours. After completion of the 
extraction process, the filtrate was concentrated to a 
dry mass by using rotavac evaporator. The extract was 
stored in a desiccator at room temperature. The 
percentage yield obtained of EETP was 2.6% w/w. 
 
Phytochemical screening 
The EETP (500 mg) was dissolved in 100 mL of its 
mother solvent ethanol and used for phytochemical 
screening. Different chemical tests were carried out to 
detect the presence of sterol, flavonoids, alkaloids, 
glycosides, tannins and saponins. The test included 
were salkowski reaction, liebermann’s reaction, 
dragendroff’s reaction, mayer’s test, wagner’s test, 
hager’s test, keller-kiliani test, shinoda test, lead 
acetate test etc19. 
Animals 
Sprague Dawley healthy male rats (180-200 g) 
were obtained from the Glenmark Research Center, 
Mahape, Navi Mumbai. The rats were housed in the 
animal house of Bharati Vidyapeeth’s College of 
Pharmacy, Navi Mumbai at 23±2 °C and 50-65% 
humidity under a 12:12 hour light and dark cycle. The 
animals were fed with standard rat pellets and water 
ad libitum throughout the study. The study was 
approved by the institutional animal ethics committee 
(Protocol no. BVCP/IAEC/06/2017), and all the 
animal experiments were carried out according to 
CPCSEA guidelines. 
Drosophila melanogaster wild type, Canton special 
strain was obtained from the Indian Institute of 
Science and Education Research, Pune, India. The 
flies were grown in 2.5 cm × 14 cm vials containing 5 
mL of a standard medium (8.3%, w/v maize flour; 
5%, w/v glucose; 2.5%, w/v sucrose; 1.5%, w/v agar; 
2%, w/v yeast powder; 0.04%, v/w propionic acid; 
0.6%, v/w orthophosphoric acid; 0.7%, v/w methyl 
hydroxybenzoate) at constant temperature and 
humidity (23±1°C; 60% relative humidity, respectively) 
under 12 h dark/light cycle. All experiments were 
performed with the same strain. Studies using flies are 




Haloperidol induced catalepsy in rat 
The rats were acclimatized for 7 days before the 
study. 40 rats were divided into 5 groups with 8 rats 
per group. Group I as vehicle control [0.5% carboxy 
methyl cellulose (CMC)], group II as disease control, 
group III (EETP 100 mg/kg of body weight) and 
group IV (EETP 200 mg/kg of body weight) as 
treatment groups and Group V as a standard group 
(levodopa 100 mg/kg +carbidopa 25 mg/kg of body 
weight). The treatment was given by peroral route 
followed by haloperidol challenge (1 mg/kg; i.p. 
route) to all groups except group I daily for 15 days. 
After induction of catalepsy with haloperidol, 
evaluation for behavioural parameters was done on 
day 7 and 13 for rotarod test; on day 8 and 14 for bar 
test; and on day 9 and 15 locomotor activity test. On 
day 15th after behavioural parameters assessment, the 
animals were sacrificed by exposing them to CO2 
overdose in the euthanasia chamber. The brain was 
excised out immediately and rinsed with ice-cold 
isotonic saline. The 10% w/v brain tissue homogenate 
was centrifuged at 10000 rpm for 15 minutes in 0.1 M 
phosphate buffer. The supernatant was used for 




biochemical estimation of lipid peroxidation, catalase 
and reduced glutathione20. 
 
Estimation of the behavioural parameter by rotarod activity 
The rotarod test is widely used in rodents to assess 
their “minimal neurological deficit” which hampers 
the muscle rigidity and affects motor function and 
coordination. Each rat was given a prior training 
before taking actual activity. Animals were placed on 
the rotating rod with a diameter of 7 cm (speed 12 
rpm). Each rat was subjected for rotarod activity at an 
interval of 30 minutes for 3 hours following cut-off 
time of 180 seconds was maintained throughout the 
experiment. The average results were recorded as the 
fall of time21. 
 
Estimation of the behavioural parameter by bar test 
Catalepsy is characterised as a reduced ability to 
initiate movement and a failure to correct abnormal 
posture, was assessed using the bar test. To measure 
catalepsy, both the front paws of rats were placed on  
9 cm horizontal bar in half rearing position which is 
parallel to the base. Rats were observed to record  
the time of removal of one paw from the bar.  
The maximum cut off time for observation was fixed 
at 180 sec22. 
 
Estimation of the behavioural parameter by locomotor activity 
The locomotor activity was monitored by using 
photoactometer (activity cage) for measurement of 
akinesia or hypokinesia. Before subjecting the 
animals to a cognitive task, they were individually 
placed in the activity meter and the total activity count 
was registered for 5 min. The locomotor activity was 
expressed in terms of total photobeam counts per  
5 minutes per animal23. 
 
Estimation of biochemical parameters: Lipid peroxidation  
The quantitative measurement of malondialdehyde 
(MDA) was used as an indirect measure of lipid 
peroxidation and was determined by reaction with 
thiobarbituric acid (TBA). Exactly 1 mL of aliquots  
of supernatant was placed in test tubes and added  
3 mL of TBA reagent: TBA 0.38% (w/w), 0.25M 
hydrochloric acid (HCl), and trichloroacetic acid 
(TCA 15%). The solution was shaken and placed for 
15 min, followed by cooling on an ice bath. After 
cooling, the solution was centrifuged to 3500 g for  
10 minutes. The upper layer was collected after the 
formation of pink colour and absorbance taken at  
532 nm on spectrophotometer24. Results were 
expressed as nanomoles per mg of protein. 
Estimation of biochemical parameters: Catalase (CAT level) 
The CAT activity was measured according to the 
method of Aebi25. The assay mixture consists of  
0.05 mL of supernatant (10% w/v) of brain tissue 
homogenate and 1.95 mL of 50 mM phosphate buffer 
(pH 7.0) in 3 mL cuvette. After adding 1 mL of  
30 mM hydrogen peroxide (H2O2), changes in 
absorbance were followed for 30 seconds at 240 nm  
at 15 seconds intervals. The millimolar extinction 
coefficient of H2O2 (0.071 mmol/cm) was used to 
calculate and the activity was expressed as 
micromoles of H2O2 oxidized per minute per 
milligram protein. 
 
Estimation of biochemical parameters: Reduced glutathione 
(GSH Level) 
For the estimation of GSH, the 1 mL of tissue 
homogenate was precipitated with 1 mL of 10% TCA. 
To an aliquot of the supernatant, 4 mL of phosphate 
solution and 0.5 mL of 5,5-dithiobis-(2-nitrobenzoic 
acid) (DTNB) reagent were added and absorbance 
was taken at 412 nm. The values were expressed as 
nanoMoles of reduced glutathione per mg of protein26. 
 
Rotenone induced locomotor deficits in Drosophila 
melanogaster 
ROT treated flies were exposed to low and high 
doses of EETP mixed in the culture medium. EETP 
was added in the medium at final concentrations of  
5 mg/mL and 10 mg/mL to give (0.05% w/v and 0.1% 
w/v). Vials of PD flies without test compound were 
used as control. Adult flies of 7–8 days old were 
divided into four groups: group I as Control group, 
group II as the disease control group (ROT 500 μM), 
group III as EETP (0.05% w/v) plus ROT, group IV 
as EETP (0.1% w/v) plus ROT. The total food 
medium contained a volume of 1% of dimethyl 
sulfoxide (DMSO), ROT or ROT plus EETP. The 
flies were exposed to treatments for 7 days before 
being used for the assay. 
 
Measurement of locomotor deficits 
 
Negative geotaxis assay 
The motor function was assessed using a negative 
geotaxis assay. During their light cycle, 15 flies were 
transferred into a graduated flat bottom glass vial 
(length 12 cm; diameter 2 cm) and allowed to 
habituate for at least 5 minutes. The vial was gently 
tapped at the bottom and observed for 60 seconds for 
the climbing activity. Locomotor behaviour was 
expressed as per cent flies escaping beyond a 
minimum distance of 10 cm in 60 seconds27. 





All the data were expressed as mean±standard 
deviation (SD). Statistical significance was tested 
using one way ANOVA followed by Tukey’s multiple 
comparisons test using Prism graph pad version 7.0 
(Graph pad software, Inc., CA, USA). *P <0.05 was 





The preliminary phytochemical analysis of the 
EETP showed the presence of sterols, alkaloids, 
tannins, flavonoids and saponins. 
 
Estimation of behavioural parameters 
 
Rotarod activity 
Animals treated with a low dose of EETP (100 
mg/kg) along with haloperidol (1 mg/kg) for 15 days 
showed a nonsignificant (P <0.05) activity on 7th and 
13th day in the latency of fall when compared to the 
disease control group. Animals treated with a high 
dose of EETP (200 mg/kg) along with haloperidol (1 
mg/kg) for 15 days showed a nonsignificant activity 
on 7th day (Table 1) while; significant (P <0.05) 
improvement was seen on 13th day (Table 1) in the 
latency of fall after 120 minutes of haloperidol 
challenge when compared to the disease control 
group. Animals treated with the standard drug 
(levodopa+carbidopa 100+25 mg/kg) along with 
haloperidol (1 mg/kg) for 15 days have shown 
significant (P <0.05) improvement in the latency of 
fall after 30 min. of haloperidol challenge on both 7th 
and 13th day (Table 1). 
 
Bar test 
Animals treated with a low dose of EETP (100 
mg/kg) along with haloperidol (1 mg/kg) for 15 days 
showed nonsignificant (P <0.05) activity on 8th and 
14th day in the reduction of cataleptic time when 
compared to the disease control group. Animals 
treated with a high dose of EETP (200 mg/kg) along 
with haloperidol (1 mg/kg) for 15 days showed a 
significant (P <0.05) improvement in reduction of 
cataleptic time on 8th and 14th day after 90 minutes 
(Table 2) of haloperidol challenge when compared to 
the disease control group. Animals treated with the 
standard drug (levodopa+carbidopa 100+25 mg/kg) 
along with haloperidol (1 mg/kg) for 15 days have 
shown significant (P <0.05) improvement in reduction 
of cataleptic time after 30 minutes of haloperidol 
challenge on both 8th and 14th day (Table 2). 
 
Locomotor activity 
Animals treated with a low dose of EETP  
(100 mg/kg) along with haloperidol (1 mg/kg) for  
15 days showed significant (P <0.05) activity on 9th 
and 15th day in the locomotor activity after 90 min. of 
haloperidol challenge when compared to the disease 
control group. Animals treated with a high dose of 
EETP (200 mg/kg) along with haloperidol (1 mg/kg) 
for 15 days showed a significant (P <0.05) locomotor 
activity on 9th day (Table 3) after 90 minutes  
of haloperidol challenge, significant (p <0.05) 
 




improvement was seen on 15th day (Table 3) in 
locomotor activity after 60 minutes of haloperidol 
challenge when compared to the disease control 
group. Animals treated with the standard drug 
(levodopa+carbidopa 100+25 mg/kg) along with 
haloperidol (1 mg/kg) for 15 days have shown 
significant (P <0.05) improvement in locomotor 
activity after 30 min. of haloperidol challenge on both 
9th and 15th day (Table 3). 
 
 
Estimation of biochemical parameters 
Administration of haloperidol intraperitoneally 
resulted in significant changes in biochemical 
parameters when compared to the vehicle control 
animals. The administration of haloperidol-induced 
oxidative stress is indicated by increased MDA level 
and decreased CAT and GSH levels when compared 
to vehicle control animals. The treatment with  
EETP (100 and 200 mg/kg, p.o.) showed significant  
 
Table 2 — Effect of EETP on cataleptic activity using bar test 





8thDAY (Activity in seconds) 
30 6.25±2.19 180.00±0.00 179.00±2.83 178.75±2.82 168.12±2.53* 
60 5.12±1.81 178.87±2.10 178.00±2.83 175.87±4.45 164.12±2.10* 
90 4.25±1.49 176.25±3.15 173.12±2.59 170.87±4.16* 155.25±2.23* 
120 4.50±1.51 172.87±3.68 167.62±4.90 164.75±4.77* 145.87±2.42* 
150 4.12±1.46 167.50±6.02 161.50±5.15 158.00±3.78* 130.87±2.53* 
180 4.87±1.55 161.37±6.86 155.75±5.01 152.87±3.09* 116.50±2.67* 
14thDAY (Activity in seconds) 
30 5.25±1.75 180.00±0.00 178.75±2.82 179.5±1.41 179.00±2.45* 
60 5.00±1.20 178.87±1.46 176.50±2.98 176.12±2.85 175.87±2.17* 
90 6.00±2.62 175.75±2.05 173.85±3.14 169.25±2.33* 169.25±2.36* 
120 5.62±2.62 173.00±2.45 168.12±6.77 161.87±1.64* 163.12±1.89* 
150 6.75±2.71 166.62±6.21 164.25±5.70 158.05±1.64* 156.37±2.72* 
180 5.75±1.91 164.37±3.62 157.37±5.42* 152.87±5.41* 148.12±2.36* 
Values are expressed as mean ± SD; n=8, where n is the number of animals per group. *indicates there is a significant difference with
P <0.05 when compared with disease group by One-way ANOVA followed by Tukey’s multiple comparisons test. Time in minutes








(P <0.05) decrease in MDA level while; significantly 
(P <0.05) increased the levels of GSH and CAT in  
the brain as compared to the disease control group 
(Table 4). 
 
Rotenone induced locomotor deficits in Drosophila 
melanogaster 
 
Negative geotaxis assay 
The results of this study revealed that the response 
of the PD induced flies was significantly lower than 
that of control flies. Measurement of the locomotor 
deficits among flies of ROT treated exhibited severe 
locomotor impairments as evident by a large number 
of flies (84.46%) staying at the bottom of the glass 
vial. The flies co-treated with EETP (0.05 and 0.1% 
w/v) significantly (P <0.05) improved the locomotor 
activity when compared with ROT treated flies  
(Table 5). The number of flies staying at the bottom 
of the vial was decreased to 51.13% when cotreated 
with a higher dose of EETP. The flies showed 
negative geotaxis behaviour treated with EETP dose-
dependently; indicating its neuroprotective effect. 
 
Discussion 
PD is a chronic neurodegenerative disease caused 
by depletion of dopamine, due to degeneration of 
dopaminergic neurons in substantia nigra pars 
compacta of basal ganglia region of the brain and 
intraneuronal deposition of Lewy bodies caused by 
aggregation of α-synuclein proteins28. The main 
clinical characteristics of PD include motor symptoms 
like tremors in the jaw, head hands, arms, or legs, 
rigidity or stiffness of the limbs and trunk; bradykinesia, 
or slowness of movement; and abnormalities in postural 
stability, or impaired balance and festinating gait3. 
In the present study, we evaluated the 
neuroprotective effect of ethanolic extract of  
Tridax procumbens on haloperidol-induced catalepsy 
in rats and ROT induced locomotor deficits in flies of 
the PD model. 
Chronic use of antipsychotics like haloperidol 
causes extrapyramidal syndrome which affects the 
motor coordination systems. Haloperidol induced 
catalepsy is a broadly accepted animal model of PD. 
Haloperidol is a nonselective D2 dopamine antagonist 
which provides a pharmacological model of 
parkinsonism for experimentation by interfering with 
the storage of catecholamine’s intracellularly, 
resulting in dopamine reduction in nerve endings23. 
The various phytochemical classes present in EETP 
have active chemical components which cross the 
blood-brain barrier to reach the various target sites  
in the brain. The Tridax procumbens is reported  
to contain many important phytoconstituents  
having significant pharmacological importance e.g. 
galgravin, luteolin, kaempferol, ellagic acid, catechin 
and silymarin18. These phytoconstituents are  
reported to have antioxidant, anti-inflammatory and 
neuroprotective activity ameliorates to revitalise and 
strengthen the neurons to perform various cognitive 
functions. These reported activities of the 
phytoconstituents suggest its possible role in the 
treatment of PD. 
In the present study, haloperidol (1 mg/kg, i.p.) 
induced significant catalepsy in rats as evidenced by a 
significant increase in the time spent on the horizontal 
Table 4 — Effect of EETP on the levels of lipid peroxidation (MDA), catalase (CAT) and reduced glutathione (GSH) in the brain of 
haloperidol challenged animals 
Groups MDA 
(nM/mg of protein) 
CAT (𝜇moles of H2O2 
used/min/mg protein) 
GSH 
(nM/mg of protein) 
Vehicle control 0.57±0.07 3.52±1.43 4.40±0.19 
Disease control 1.59±0.11 1.13±0.23 3.45±0.17 
EETP 100 mg/kg 1.33±0.03* 2.89±0.27* 4.08±0.27* 
EETP 200 mg/kg 1.12±0.02* 3.45±0.27* 4.37±0.18* 
Standard 0.88±0.05* 2.75±0.35* 6.24±0.35* 
Values are expressed as mean ± SD; n=8, where n is the number of animals per group. *indicates there is a significant difference with  
P <0.05 when compared with disease group One-way ANOVA followed by Tukey’s multiple comparisons test. 
 
Table 5 — Effect of EETP on locomotor activity of Drosophila melanogaster as evaluated by negative geotaxis assay 




No. of flies escaped 









Values are expressed as mean±SD; n=15, where n is the number of flies per group. *indicates there is a significant difference with 
P <0.05 when compared with disease group One-way ANOVA followed by Tukey’s multiple comparisons test. Values in parenthesis are
expressed as % protection against rotenone-induced locomotor deficits 




bar and caused a significant decrease in locomotor 
activity and muscle activity as compared to vehicle 
control animals. Both the doses of EETP were not 
showing a significant effect on 7 days of treatment; 
while standard drug showed a significant effect on 
Day 7. The low and high dose EETP (200 mg/kg) 
showed a similar protective effect against haloperidol-
induced catalepsy exhibited a significant reduction in 
catalepsy, increase in locomotor activity and  
muscle rigidity activity after treatment of 15 days. 
The reduction in catalepsy and improved locomotor 
activity was comparable to that of protective action 
exhibited by the standard drug. It can be predicted 
that the required concentration of EETP to give 
significant protective effect is achieved as a virtue of 
cumulative accumulation in the body and hence 
significant efficacy was found after 15 days of 
treatment. 
Oxidative stress generated as a result of 
mitochondrial complex-1 dysfunction plays an 
important role in the pathogenesis of PD. The 
oxidative stress parameters were measured through 
the determination of levels of lipid peroxidation, 
catalase and reduced glutathione in the brain tissue. 
Lipid peroxidation, a reactive marker of oxidative 
stress, was estimated by measuring the levels of 
MDA. Lipid peroxidation occurs due to attack by 
reactive free radicals on the double bond of 
unsaturated fatty acid and arachidonic acid which 
produces lipid peroxyl radicals and that initiate a 
chain reaction, which further attacks on other 
unsaturated fatty acids. As we know, lipid 
peroxidation is the process of oxidative degradation of 
polyunsaturated fatty acids and its occurrence in 
biological membranes causes impaired membrane 
function and structural integrity29, decreased fluidity, 
and inactivation of some membrane-bound enzymes. 
In the present investigation, similar results were 
observed in the brain homogenate of haloperidol 
treated disease control group. After treatment with 
EETP (100 and 200 mg/kg) significantly reduction in 
lipid peroxidation level was found when compared 
with the disease control group. 
Catalase is an antioxidant enzyme which helps in 
neutralizing the harmful effects of hydrogen peroxide. 
Catalase converts hydrogen peroxide to form water 
and nonreactive oxygen species, thus preventing the 
accumulation of precursor to free radical biosynthesis. 
Oxidative stress results in a decrease in catalase level. 
During induction of catalepsy with haloperidol in rats 
induced oxidative stress, as indicated by a decrease in 
the catalase levels. After treatment with EETP (100 
and 200 mg/kg) significantly increment in catalase 
level was found when compared with the disease 
control group. 
The depletion of reduced glutathione in the 
substantia nigra in PD could be the result of neuronal 
loss due to oxidative stress of free radicals. A positive 
correlation has been found to exist between the level 
of neuronal loss and reduction of glutathione30. 
Reduction in the availability of reduced glutathione 
would impair the ability of neurons to neutralise 
hydrogen peroxide and increase the risk of free 
radical formation and lipid peroxidation. A reduction 
in GSH levels was evident in haloperidol treated 
disease control animals. After treatment with EETP 
(100 and 200 mg/kg) significantly increment in GSH 
level was found when compared with the disease 
control group. 
Thus, the haloperidol-induced disease control 
group showed a significant increase in the levels of 
lipid peroxidation and a decrease in the levels of 
catalase and GSH in the brain as compared to the 
vehicle-treated control animals. All these indicate an 
increase in the oxidative stress in the brain of animals 
treated with haloperidol. Pre-treatment with EETP 
(100 and 200 mg/kg) resulted in a decrease in lipid 
peroxidation and increase in the levels of catalase, and 
GSH, indicating its free radical scavenging effect in 
the brain of haloperidol treated animals. The activity 
of EETP at both doses is comparable to the  
standard drug.  
In the Drosophila model, ROT is commonly used 
for the PD model. It has a high affinity specific 
inhibitor of mitochondrial (complex I) NADH 
dehydrogenase. Being highly lipophilic, it crosses the 
blood-brain barrier rapidly and accumulates in 
subcellular organelles like mitochondria31; where 
oxidative damage leads to neurotoxicity of 
dopaminergic neurons and locomotor deficits32,33. In 
ROT (500 μM) induced significant locomotor 
impairment in flies as indicated by a large number of 
flies remaining at bottom of vials in the disease 
control group. The EETP at doses of 0.05 and 0.1% 
w/v showed a protective effect against ROT induced 
locomotor impairment exhibited significant 
improvement in locomotor activity, thus could be 
proved with possible action on central nervous system 
indicates that EETP has an ability of free radical 
scavenging properties helps in neuroprotection of 
dopaminergic neurons in the brain. 





The results of the present study conclusively 
showed that EETP has free radical scavenging activity 
and neuroprotective role in experimental models of 
PD. Hence, the neuromodulatory effect of EETP on 
behavioural, oxidative stress may be due to its 
neuroprotective and free radical scavenging 
properties. Further detailed molecular studies, and 
also further characterization and isolation of active 
constituents responsible for the neuroprotective effect 
should be undertaken. 
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